These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 23486550

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine for the prevention of genital warts in males: profile report. demail@springer.com.
    Garnock-Jones KP, Giuliano AR.
    Drugs R D; 2012 Dec 01; 12(4):235-8. PubMed ID: 23017129
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
    Martín-Merino E, Llorente-García A, Castillo Cano B, Montero Corominas D, Huerta-Álvarez C.
    Pharmaceut Med; 2019 Dec 01; 33(6):519-530. PubMed ID: 31933243
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males.
    Garnock-Jones KP, Giuliano AR.
    Drugs; 2011 Mar 26; 71(5):591-602. PubMed ID: 21443282
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
    Kim JJ.
    Lancet Infect Dis; 2010 Dec 26; 10(12):845-52. PubMed ID: 21051295
    [Abstract] [Full Text] [Related]

  • 56. Potential impact of the human papillomavirus vaccine on the incidence proportion of genital warts in French women (EFFICAE study): a multicentric prospective observational study.
    Judlin P, Jacquard AC, Carcopino X, Aubin F, Dahlab A, Mistretta F, Not D, Boelle PY, Aynaud O, Soubeyrand B.
    Sex Health; 2016 Feb 26; 13(1):49-54. PubMed ID: 26567557
    [Abstract] [Full Text] [Related]

  • 57. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review.
    Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R.
    Adv Ther; 2015 Jan 26; 32(1):10-30. PubMed ID: 25620536
    [Abstract] [Full Text] [Related]

  • 58. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
    Silverberg MJ, Leyden WA, Lam JO, Gregorich SE, Huchko MJ, Kulasingam S, Kuppermann M, Smith-McCune KK, Sawaya GF.
    Lancet Child Adolesc Health; 2018 Oct 26; 2(10):707-714. PubMed ID: 30236379
    [Abstract] [Full Text] [Related]

  • 59. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women--an ecological study.
    Sandø N, Kofoed K, Zachariae C, Fouchard J.
    Acta Derm Venereol; 2014 May 26; 94(3):288-92. PubMed ID: 24150529
    [Abstract] [Full Text] [Related]

  • 60. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study.
    Grönlund O, Herweijer E, Sundström K, Arnheim-Dahlström L.
    J Intern Med; 2016 Dec 26; 280(6):618-626. PubMed ID: 27478093
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.